U.S. markets open in 4 hours 9 minutes
  • S&P Futures

    3,738.50
    +48.25 (+1.31%)
     
  • Dow Futures

    29,854.00
    +316.00 (+1.07%)
     
  • Nasdaq Futures

    11,478.75
    +193.00 (+1.71%)
     
  • Russell 2000 Futures

    1,741.20
    +26.30 (+1.53%)
     
  • Crude Oil

    83.91
    +0.28 (+0.33%)
     
  • Gold

    1,715.10
    +13.10 (+0.77%)
     
  • Silver

    20.88
    +0.29 (+1.41%)
     
  • EUR/USD

    0.9860
    +0.0033 (+0.34%)
     
  • 10-Yr Bond

    3.6510
    0.0000 (0.00%)
     
  • Vix

    29.27
    -2.35 (-7.43%)
     
  • GBP/USD

    1.1352
    +0.0032 (+0.28%)
     
  • USD/JPY

    144.7660
    +0.1460 (+0.10%)
     
  • BTC-USD

    19,856.79
    +685.19 (+3.57%)
     
  • CMC Crypto 200

    451.49
    +16.13 (+3.71%)
     
  • FTSE 100

    7,025.49
    +116.73 (+1.69%)
     
  • Nikkei 225

    26,992.21
    +776.42 (+2.96%)
     

Cassava Insiders Got A Lot Richer As Shares Rebound Following Refutation of Data Manipulation Claims

·1 min read
  • Journal of Prevention of Alzheimer's Disease (JPAD) informed Cassava Sciences Inc (NASDAQ: SAVA) about no convincing evidence to support data manipulation allegations in a 2020 paper on simufilam co-authored by the company's personnel and its science collaborators.

  • Simufilam, Cassava's Alzheimer's candidate, is a small molecule (oral) drug that restores the normal shape and function of altered filamin A protein in the brain.

  • "From the onset, I have said that allegations of research misconduct are false, and for a good reason – I see no supporting evidence for the allegations," said Remi Barbier, President & CEO.

  • "I'm hopeful that written pronouncements from neutral and independent science experts will help close the chapter of baseless attacks against our science."

  • Related Content: Cassava Sciences Shares Plunge After Criminal Investigation Report.

  • In May 2022, Neurobiology of Aging investigated and found no evidence of data manipulation in a paper on simufilam published in that journal in 2017.

  • In December 2021, Cassava Sciences announced that Neuroscience investigated and found no evidence of data manipulation in a paper published in 2005.

  • In November 2021, Cassava Sciences announced that The Journal of Neuroscience investigated and found no evidence of data manipulation in a paper on simufilam published in July 2012.

  • Price Action: SAVA shares are up 1.79% at $26.18 on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.